Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model

Terry Jo V. Bichell, Michal Wegrzynowicz, K. Grace Tipps, Emma M. Bradley, Michael A. Uhouse, Miles Bryan, Kyle Horning, Nicole Fisher, Karrie Dudek, Timothy Halbesma, Preethi Umashanker, Andrew D. Stubbs, Hunter K. Holt, Gunnar F. Kwakye, Andrew M. Tidball, Roger J. Colbran, Michael Aschner, M. Diana Neely, Alba Di Di Pardo, Vittorio MaglioneAlexander Osmand, Aaron B. Bowman

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Huntington's disease (HD) is caused by a mutation in the huntingtin gene (HTT), resulting in profound striatal neurodegeneration through an unknown mechanism. Perturbations in the urea cycle have been reported in HD models and in HD patient blood and brain. In neurons, arginase is a central urea cycle enzyme, and the metal manganese (Mn) is an essential cofactor. Deficient biological responses to Mn, and reduced Mn accumulation have been observed in HD striatal mouse and cell models. Here we report in vivo and ex vivo evidence of a urea cycle metabolic phenotype in a prodromal HD mouse model. Further, either in vivo or in vitro Mn supplementation reverses the urea-cycle pathology by restoring arginase activity. We show that Arginase 2 (ARG2) is the arginase enzyme present in these mouse brain models, with ARG2 protein levels directly increased by Mn exposure. ARG2 protein is not reduced in the prodromal stage, though enzyme activity is reduced, indicating that altered Mn bioavailability as a cofactor leads to the deficient enzymatic activity. These data support a hypothesis that mutant HTT leads to a selective deficiency of neuronal Mn at an early disease stage, contributing to HD striatal urea-cycle pathophysiology through an effect on arginase activity.

Original languageEnglish (US)
Pages (from-to)1596-1604
Number of pages9
JournalBiochimica et Biophysica Acta - Molecular Basis of Disease
Volume1863
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

Corpus Striatum
Arginase
Huntington Disease
Manganese
Urea
Pathology
Enzymes
Prodromal Symptoms
Brain
Biological Availability
Genes
Proteins
Metals
Phenotype
Neurons
Mutation

Keywords

  • Arginase
  • Huntington's
  • Manganese
  • Neurodegeneration
  • Striatum
  • Urea

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Cite this

Bichell, T. J. V., Wegrzynowicz, M., Tipps, K. G., Bradley, E. M., Uhouse, M. A., Bryan, M., ... Bowman, A. B. (2017). Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1863(6), 1596-1604. https://doi.org/10.1016/j.bbadis.2017.02.013

Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model. / Bichell, Terry Jo V.; Wegrzynowicz, Michal; Tipps, K. Grace; Bradley, Emma M.; Uhouse, Michael A.; Bryan, Miles; Horning, Kyle; Fisher, Nicole; Dudek, Karrie; Halbesma, Timothy; Umashanker, Preethi; Stubbs, Andrew D.; Holt, Hunter K.; Kwakye, Gunnar F.; Tidball, Andrew M.; Colbran, Roger J.; Aschner, Michael; Neely, M. Diana; Di Pardo, Alba Di; Maglione, Vittorio; Osmand, Alexander; Bowman, Aaron B.

In: Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1863, No. 6, 01.06.2017, p. 1596-1604.

Research output: Contribution to journalArticle

Bichell, TJV, Wegrzynowicz, M, Tipps, KG, Bradley, EM, Uhouse, MA, Bryan, M, Horning, K, Fisher, N, Dudek, K, Halbesma, T, Umashanker, P, Stubbs, AD, Holt, HK, Kwakye, GF, Tidball, AM, Colbran, RJ, Aschner, M, Neely, MD, Di Pardo, AD, Maglione, V, Osmand, A & Bowman, AB 2017, 'Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model', Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1863, no. 6, pp. 1596-1604. https://doi.org/10.1016/j.bbadis.2017.02.013
Bichell, Terry Jo V. ; Wegrzynowicz, Michal ; Tipps, K. Grace ; Bradley, Emma M. ; Uhouse, Michael A. ; Bryan, Miles ; Horning, Kyle ; Fisher, Nicole ; Dudek, Karrie ; Halbesma, Timothy ; Umashanker, Preethi ; Stubbs, Andrew D. ; Holt, Hunter K. ; Kwakye, Gunnar F. ; Tidball, Andrew M. ; Colbran, Roger J. ; Aschner, Michael ; Neely, M. Diana ; Di Pardo, Alba Di ; Maglione, Vittorio ; Osmand, Alexander ; Bowman, Aaron B. / Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model. In: Biochimica et Biophysica Acta - Molecular Basis of Disease. 2017 ; Vol. 1863, No. 6. pp. 1596-1604.
@article{da1839453ded493fb0586fef73ac2f03,
title = "Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model",
abstract = "Huntington's disease (HD) is caused by a mutation in the huntingtin gene (HTT), resulting in profound striatal neurodegeneration through an unknown mechanism. Perturbations in the urea cycle have been reported in HD models and in HD patient blood and brain. In neurons, arginase is a central urea cycle enzyme, and the metal manganese (Mn) is an essential cofactor. Deficient biological responses to Mn, and reduced Mn accumulation have been observed in HD striatal mouse and cell models. Here we report in vivo and ex vivo evidence of a urea cycle metabolic phenotype in a prodromal HD mouse model. Further, either in vivo or in vitro Mn supplementation reverses the urea-cycle pathology by restoring arginase activity. We show that Arginase 2 (ARG2) is the arginase enzyme present in these mouse brain models, with ARG2 protein levels directly increased by Mn exposure. ARG2 protein is not reduced in the prodromal stage, though enzyme activity is reduced, indicating that altered Mn bioavailability as a cofactor leads to the deficient enzymatic activity. These data support a hypothesis that mutant HTT leads to a selective deficiency of neuronal Mn at an early disease stage, contributing to HD striatal urea-cycle pathophysiology through an effect on arginase activity.",
keywords = "Arginase, Huntington's, Manganese, Neurodegeneration, Striatum, Urea",
author = "Bichell, {Terry Jo V.} and Michal Wegrzynowicz and Tipps, {K. Grace} and Bradley, {Emma M.} and Uhouse, {Michael A.} and Miles Bryan and Kyle Horning and Nicole Fisher and Karrie Dudek and Timothy Halbesma and Preethi Umashanker and Stubbs, {Andrew D.} and Holt, {Hunter K.} and Kwakye, {Gunnar F.} and Tidball, {Andrew M.} and Colbran, {Roger J.} and Michael Aschner and Neely, {M. Diana} and {Di Pardo}, {Alba Di} and Vittorio Maglione and Alexander Osmand and Bowman, {Aaron B.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.bbadis.2017.02.013",
language = "English (US)",
volume = "1863",
pages = "1596--1604",
journal = "Biochimica et Biophysica Acta - Molecular Basis of Disease",
issn = "0925-4439",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model

AU - Bichell, Terry Jo V.

AU - Wegrzynowicz, Michal

AU - Tipps, K. Grace

AU - Bradley, Emma M.

AU - Uhouse, Michael A.

AU - Bryan, Miles

AU - Horning, Kyle

AU - Fisher, Nicole

AU - Dudek, Karrie

AU - Halbesma, Timothy

AU - Umashanker, Preethi

AU - Stubbs, Andrew D.

AU - Holt, Hunter K.

AU - Kwakye, Gunnar F.

AU - Tidball, Andrew M.

AU - Colbran, Roger J.

AU - Aschner, Michael

AU - Neely, M. Diana

AU - Di Pardo, Alba Di

AU - Maglione, Vittorio

AU - Osmand, Alexander

AU - Bowman, Aaron B.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Huntington's disease (HD) is caused by a mutation in the huntingtin gene (HTT), resulting in profound striatal neurodegeneration through an unknown mechanism. Perturbations in the urea cycle have been reported in HD models and in HD patient blood and brain. In neurons, arginase is a central urea cycle enzyme, and the metal manganese (Mn) is an essential cofactor. Deficient biological responses to Mn, and reduced Mn accumulation have been observed in HD striatal mouse and cell models. Here we report in vivo and ex vivo evidence of a urea cycle metabolic phenotype in a prodromal HD mouse model. Further, either in vivo or in vitro Mn supplementation reverses the urea-cycle pathology by restoring arginase activity. We show that Arginase 2 (ARG2) is the arginase enzyme present in these mouse brain models, with ARG2 protein levels directly increased by Mn exposure. ARG2 protein is not reduced in the prodromal stage, though enzyme activity is reduced, indicating that altered Mn bioavailability as a cofactor leads to the deficient enzymatic activity. These data support a hypothesis that mutant HTT leads to a selective deficiency of neuronal Mn at an early disease stage, contributing to HD striatal urea-cycle pathophysiology through an effect on arginase activity.

AB - Huntington's disease (HD) is caused by a mutation in the huntingtin gene (HTT), resulting in profound striatal neurodegeneration through an unknown mechanism. Perturbations in the urea cycle have been reported in HD models and in HD patient blood and brain. In neurons, arginase is a central urea cycle enzyme, and the metal manganese (Mn) is an essential cofactor. Deficient biological responses to Mn, and reduced Mn accumulation have been observed in HD striatal mouse and cell models. Here we report in vivo and ex vivo evidence of a urea cycle metabolic phenotype in a prodromal HD mouse model. Further, either in vivo or in vitro Mn supplementation reverses the urea-cycle pathology by restoring arginase activity. We show that Arginase 2 (ARG2) is the arginase enzyme present in these mouse brain models, with ARG2 protein levels directly increased by Mn exposure. ARG2 protein is not reduced in the prodromal stage, though enzyme activity is reduced, indicating that altered Mn bioavailability as a cofactor leads to the deficient enzymatic activity. These data support a hypothesis that mutant HTT leads to a selective deficiency of neuronal Mn at an early disease stage, contributing to HD striatal urea-cycle pathophysiology through an effect on arginase activity.

KW - Arginase

KW - Huntington's

KW - Manganese

KW - Neurodegeneration

KW - Striatum

KW - Urea

UR - http://www.scopus.com/inward/record.url?scp=85018958895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018958895&partnerID=8YFLogxK

U2 - 10.1016/j.bbadis.2017.02.013

DO - 10.1016/j.bbadis.2017.02.013

M3 - Article

C2 - 28213125

AN - SCOPUS:85018958895

VL - 1863

SP - 1596

EP - 1604

JO - Biochimica et Biophysica Acta - Molecular Basis of Disease

JF - Biochimica et Biophysica Acta - Molecular Basis of Disease

SN - 0925-4439

IS - 6

ER -